Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Traxion Sab De Cv Ord Shs GRPOF

Grupo Traxion SAB de CV is a Mexico-based company engaged in the transportation sector. The Company provides logistics services within eight business areas: Fright, including intermodal and multimodal services, door-to-door, national and cross-border distribution, among others; Integrated logistics, including logistics management, aerial and maritime services and custom transportation support services; Warehousing, including dedicated storage, shared warehouses, packing and value-added services, such as labeling and products assembly; Logistics systems, including software for logistics management; Passenger transportation, including transportation of personnel and students; Special services, including rental of bus and vans; Moving, including national and international moving services, and Advertising, including custom transportation services during marketing campaigns. The Company operates through a number of group companies.


PINL:GRPOF - Post by User

Post by Bellio123on Sep 02, 2020 8:13am
385 Views
Post# 31492699

TETRA PLENTITUDE CLINICAL TRIAL INITIATED

TETRA PLENTITUDE CLINICAL TRIAL INITIATED

Tetra Bio-Pharma Announces Plenitude Clinical Trial is Initiated

09/02/2020

Pharmaceutical GMP grade QIXLEEF™ shipped

OTTAWA, ON / ACCESSWIRE / September 2, 2020 Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to announce that it has initiated the in-life phase of the clinical trial operations now that the investigational QIXLEEF™ drug has been shipped by Aphria Inc.

The Plenitude© trial is designed to prove the efficacy and safety of QIXLEEF™ for the relief of pain in cancer patients. This trial, and its clinical sites across the Unites States, have already received the authorizations from the US Food and Drug Administration (FDA) and the US Drug Enforcement Agency (DEA). Since the authorization from the US FDA in November 2019, Tetra has been working with Aphria Inc. to manufacture sufficient quantities of high quality pharmaceutical GMP grade QIXLEEF™ product according to upgraded specifications on drug product composition as approved by the FDA.

The Plenitude© trial involves ten clinical sites across the United States. Tetra is using a DEA-licensed centralized pharmacy to distribute QIXLEEF™ to the clinical sites and ensure random and double-blind allocation of the product to the patients in accordance with Good Clinical Practices and the USA Food and Drug regulations. With these critical pieces in place, patient recruitment, enrollment and treatment will now begin. Plenitude© is a 4-week double-blind, randomized, placebo-controlled, parallel group design trial to evaluate the safety and efficacy of inhaled QIXLEEF™ to relieve uncontrolled cancer related pain in 78 adult patients with advanced incurable disease.

Dr. Guy Chamberland, CEO and CRO commented, "last week we announced the significantly lower levels of CBD metabolites and today we are pleased to announce that QIXLEEF™ has been shipped by Aphria Inc. The Plenitude© trial has been anticipated for a long time and we are proud that the challenge of ensuring high quality pharmaceutical grade GMP product for patients with a plant-based drug has been overcome. Now, with last week's data, we are confident that we will not have any drug-related liver injury events in the trial. This is a major scientific milestone as it addresses the safety of vaporized QIXLEEF after the discouraging liver injury safety results observed in oral CBD trials for the treatment of seizures."


<< Previous
Bullboard Posts
Next >>